Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 5Phase 3 5Phase 4 3Phase 1/2 3Phase 1 3

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 256Breast Neoplasms 174Neoplasms 169Colorectal Neoplasms 153Neoplasm Metastasis 127Recurrence 120Melanoma 120Prostatic Neoplasms 118Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 115Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 94Stomach Neoplasms 92Triple Negative Breast Neoplasms 86Squamous Cell Carcinoma of Head and Neck 85Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Carcinoma, Renal Cell 64Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 56Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

radiprodil 1carbon-11 acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Tuberous Sclerosis × 1 year × Clear all
NCT06392009 2026-04-01

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

GRIN Therapeutics, Inc.

Phase 1/2 Active not recruiting
30 enrolled

Focal Cortical Dysplasia, Tuberous Sclerosis

NCT05467397 2026-01-21

Feasibility of [11C]Acetate-PET in LAM and TSC

Brigham and Women's Hospital

Phase 1/2 Active not recruiting
7 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

NCT07287202 2025-12-23

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Sovargen

Phase 1/2 Not yet recruiting
15 enrolled

Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly

Data powered by HemOnc (CC BY 4.0) Colophon âš¡